AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
nicotinic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| nicotinic acid or nicotinoyl alcohol derivatives | 2835 | 59-67-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
| 0.20 | g | P |
| 2 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 18 mg/mL | Bocci G, Oprea TI, Benet LZ |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 101.53 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 68 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -3.146 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.635 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 2.529 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.637 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 71.010 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 76.760 | % | High | 1 |
| herg | hERG pIC50 | 4.588 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.642 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.319 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 78.090 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 51 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,MAPK7,PIK3CD,PRKDC,SIK2,STK33,TGFBR1,TTK | 15 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.389 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.321 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 93.860 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.318 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 | |
| pppb | Pig plasma protein binding (% unbound) | 71.990 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.189 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 91.450 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 63.950 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 950.605 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 24, 1957 | FDA | MEDPOINTE PHARM HLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pemphigus | 164.73 | 9.84 | 6 | 52999 | 326858 | 90248584 |
| Synovitis | 159.72 | 9.84 | 8 | 52997 | 329744 | 90245698 |
| Hand deformity | 154.53 | 9.84 | 4 | 53001 | 296358 | 90279084 |
| Contraindicated product administered | 142.56 | 9.84 | 12 | 52993 | 320127 | 90255315 |
| Systemic lupus erythematosus | 137.95 | 9.84 | 23 | 52982 | 361873 | 90213569 |
| Glossodynia | 133.04 | 9.84 | 16 | 52989 | 321763 | 90253679 |
| Infusion related reaction | 128.29 | 9.84 | 42 | 52963 | 416738 | 90158704 |
| Anti-cyclic citrullinated peptide antibody positive | 120.28 | 9.84 | 4 | 53001 | 236429 | 90339013 |
| Product dose omission issue | 119.77 | 9.84 | 409 | 52596 | 291278 | 90284164 |
| Pericarditis | 117.89 | 9.84 | 11 | 52994 | 270140 | 90305302 |
| Off label use | 114.01 | 9.84 | 303 | 52702 | 1101949 | 89473493 |
| Product use in unapproved indication | 108.64 | 9.84 | 31 | 52974 | 336205 | 90239237 |
| Wound | 107.47 | 9.84 | 23 | 52982 | 302957 | 90272485 |
| Duodenal ulcer perforation | 102.14 | 9.84 | 7 | 52998 | 221281 | 90354161 |
| Fall | 99.62 | 9.84 | 549 | 52456 | 481261 | 90094181 |
| Helicobacter infection | 99.60 | 9.84 | 9 | 52996 | 226841 | 90348601 |
| Treatment failure | 98.22 | 9.84 | 28 | 52977 | 303900 | 90271542 |
| Maternal exposure during pregnancy | 96.40 | 9.84 | 45 | 52960 | 360018 | 90215424 |
| Diarrhoea | 89.42 | 9.84 | 889 | 52116 | 938301 | 89637141 |
| Drug intolerance | 84.90 | 9.84 | 82 | 52923 | 447509 | 90127933 |
| Folliculitis | 84.82 | 9.84 | 10 | 52995 | 204343 | 90371099 |
| Rheumatoid factor positive | 83.59 | 9.84 | 4 | 53001 | 171646 | 90403796 |
| Lower respiratory tract infection | 77.52 | 9.84 | 25 | 52980 | 250634 | 90324808 |
| Muscle injury | 74.94 | 9.84 | 8 | 52997 | 176646 | 90398796 |
| General physical health deterioration | 73.40 | 9.84 | 60 | 52945 | 355055 | 90220387 |
| Rheumatic fever | 73.19 | 9.84 | 4 | 53001 | 153117 | 90422325 |
| Unevaluable event | 71.79 | 9.84 | 121 | 52884 | 54727 | 90520715 |
| Product use issue | 71.66 | 9.84 | 53 | 52952 | 329866 | 90245576 |
| Therapy cessation | 65.54 | 9.84 | 93 | 52912 | 36268 | 90539174 |
| Feeling abnormal | 65.50 | 9.84 | 231 | 52774 | 167004 | 90408438 |
| Type 2 diabetes mellitus | 65.13 | 9.84 | 19 | 52986 | 203225 | 90372217 |
| Liver injury | 62.42 | 9.84 | 12 | 52993 | 170555 | 90404887 |
| Fatigue | 61.68 | 9.84 | 981 | 52024 | 1153042 | 89422400 |
| Device expulsion | 61.40 | 9.84 | 96 | 52909 | 40790 | 90534652 |
| C-reactive protein abnormal | 58.88 | 9.84 | 4 | 53001 | 127425 | 90448017 |
| Hepatic enzyme increased | 58.58 | 9.84 | 75 | 52930 | 360661 | 90214781 |
| Irritable bowel syndrome | 58.53 | 9.84 | 24 | 52981 | 207424 | 90368018 |
| Muscle spasms | 58.07 | 9.84 | 296 | 52709 | 251587 | 90323855 |
| Arthropathy | 57.58 | 9.84 | 78 | 52927 | 366164 | 90209278 |
| Sleep disorder due to general medical condition, insomnia type | 56.76 | 9.84 | 5 | 53000 | 128689 | 90446753 |
| C-reactive protein increased | 56.23 | 9.84 | 18 | 52987 | 181371 | 90394071 |
| Deep vein thrombosis | 53.01 | 9.84 | 145 | 52860 | 91475 | 90483967 |
| Back pain | 52.95 | 9.84 | 342 | 52663 | 316833 | 90258609 |
| Full blood count decreased | 52.13 | 9.84 | 75 | 52930 | 29614 | 90545828 |
| Neuropathy peripheral | 50.90 | 9.84 | 186 | 52819 | 136784 | 90438658 |
| Impaired healing | 50.34 | 9.84 | 38 | 52967 | 234161 | 90341281 |
| Intentional product use issue | 49.50 | 9.84 | 33 | 52972 | 216859 | 90358583 |
| Dizziness | 48.86 | 9.84 | 543 | 52462 | 588741 | 89986701 |
| Drug ineffective | 48.40 | 9.84 | 548 | 52457 | 1383750 | 89191692 |
| Ill-defined disorder | 48.07 | 9.84 | 24 | 52981 | 184867 | 90390575 |
| Therapeutic product effect decreased | 47.92 | 9.84 | 55 | 52950 | 277516 | 90297926 |
| Therapeutic product effect incomplete | 47.73 | 9.84 | 27 | 52978 | 193869 | 90381573 |
| Nausea | 47.43 | 9.84 | 911 | 52094 | 1109405 | 89466037 |
| Discomfort | 46.67 | 9.84 | 55 | 52950 | 274280 | 90301162 |
| Constipation | 45.97 | 9.84 | 301 | 52704 | 280094 | 90295348 |
| Joint swelling | 45.49 | 9.84 | 147 | 52858 | 503153 | 90072289 |
| Myalgia | 45.49 | 9.84 | 213 | 52792 | 174912 | 90400530 |
| Fibromyalgia | 44.93 | 9.84 | 33 | 52972 | 206236 | 90369206 |
| Swollen joint count increased | 44.77 | 9.84 | 6 | 52999 | 111200 | 90464242 |
| Blister | 44.59 | 9.84 | 50 | 52955 | 254948 | 90320494 |
| Flushing | 43.41 | 9.84 | 132 | 52873 | 88359 | 90487083 |
| Device dislocation | 43.26 | 9.84 | 71 | 52934 | 31411 | 90544031 |
| Toxicity to various agents | 41.59 | 9.84 | 65 | 52940 | 287781 | 90287661 |
| Discoloured vomit | 41.22 | 9.84 | 18 | 52987 | 1174 | 90574268 |
| Cardiac failure congestive | 40.94 | 9.84 | 139 | 52866 | 98555 | 90476887 |
| Facet joint syndrome | 40.35 | 9.84 | 5 | 53000 | 98384 | 90477058 |
| Wheezing | 38.11 | 9.84 | 50 | 52955 | 238030 | 90337412 |
| Dehydration | 37.68 | 9.84 | 218 | 52787 | 194229 | 90381213 |
| Alopecia | 37.24 | 9.84 | 156 | 52849 | 494915 | 90080527 |
| Hypercholesterolaemia | 37.11 | 9.84 | 7 | 52998 | 100885 | 90474557 |
| Plasma cell myeloma | 37.06 | 9.84 | 77 | 52928 | 40751 | 90534691 |
| Drug abuse | 36.85 | 9.84 | 3 | 53002 | 82344 | 90493098 |
| Urticaria thermal | 35.81 | 9.84 | 13 | 52992 | 520 | 90574922 |
| Tremor | 35.26 | 9.84 | 180 | 52825 | 152993 | 90422449 |
| Lip dry | 35.08 | 9.84 | 8 | 52997 | 100947 | 90474495 |
| Injection site pain | 33.82 | 9.84 | 195 | 52810 | 173504 | 90401938 |
| Haemoglobin decreased | 33.64 | 9.84 | 185 | 52820 | 161771 | 90413671 |
| Injection site bruising | 33.51 | 9.84 | 86 | 52919 | 52221 | 90523221 |
| Headache | 33.43 | 9.84 | 698 | 52307 | 862048 | 89713394 |
| Hot flush | 33.26 | 9.84 | 93 | 52912 | 59395 | 90516047 |
| Urinary tract infection | 33.19 | 9.84 | 298 | 52707 | 305334 | 90270108 |
| Rheumatoid arthritis | 31.98 | 9.84 | 107 | 52898 | 362507 | 90212935 |
| Flatulence | 31.84 | 9.84 | 73 | 52932 | 41294 | 90534148 |
| Nervousness | 31.82 | 9.84 | 65 | 52940 | 33991 | 90541451 |
| Obesity | 31.76 | 9.84 | 11 | 52994 | 105496 | 90469946 |
| Prescribed overdose | 31.49 | 9.84 | 9 | 52996 | 97616 | 90477826 |
| Joint range of motion decreased | 30.45 | 9.84 | 21 | 52984 | 135622 | 90439820 |
| Asthenia | 29.55 | 9.84 | 457 | 52548 | 533294 | 90042148 |
| Administration site erythema | 29.09 | 9.84 | 13 | 52992 | 896 | 90574546 |
| Injection site erythema | 28.71 | 9.84 | 124 | 52881 | 98378 | 90477064 |
| Nasal congestion | 28.26 | 9.84 | 110 | 52895 | 83304 | 90492138 |
| Psoriasis | 28.19 | 9.84 | 165 | 52840 | 147589 | 90427853 |
| Exposure during pregnancy | 28.06 | 9.84 | 61 | 52944 | 238349 | 90337093 |
| Epilepsy | 27.61 | 9.84 | 7 | 52998 | 82199 | 90493243 |
| Injection site haemorrhage | 27.59 | 9.84 | 55 | 52950 | 28263 | 90547179 |
| Pulmonary embolism | 27.54 | 9.84 | 150 | 52855 | 130670 | 90444772 |
| Grip strength decreased | 27.27 | 9.84 | 10 | 52995 | 92566 | 90482876 |
| Femoral artery dissection | 26.87 | 9.84 | 6 | 52999 | 37 | 90575405 |
| Condition aggravated | 26.47 | 9.84 | 222 | 52783 | 595323 | 89980119 |
| Pulmonary fibrosis | 26.40 | 9.84 | 15 | 52990 | 107488 | 90467954 |
| Wound infection | 25.91 | 9.84 | 15 | 52990 | 106387 | 90469055 |
| Pelvic pain | 25.80 | 9.84 | 38 | 52967 | 15319 | 90560123 |
| Stomatitis | 25.65 | 9.84 | 79 | 52926 | 274619 | 90300823 |
| Abdominal discomfort | 25.46 | 9.84 | 169 | 52836 | 477159 | 90098283 |
| Influenza like illness | 25.46 | 9.84 | 104 | 52901 | 80507 | 90494935 |
| Body height decreased | 25.22 | 9.84 | 33 | 52972 | 11916 | 90563526 |
| Hip fracture | 25.04 | 9.84 | 58 | 52947 | 33019 | 90542423 |
| Internal haemorrhage | 24.92 | 9.84 | 24 | 52981 | 6196 | 90569246 |
| Swelling | 24.61 | 9.84 | 144 | 52861 | 418914 | 90156528 |
| COVID-19 | 24.49 | 9.84 | 38 | 52967 | 168805 | 90406637 |
| Mobility decreased | 24.20 | 9.84 | 71 | 52934 | 250663 | 90324779 |
| Atrial fibrillation | 24.08 | 9.84 | 147 | 52858 | 133464 | 90441978 |
| Gastrointestinal disorder | 23.83 | 9.84 | 74 | 52931 | 256613 | 90318829 |
| Chills | 23.65 | 9.84 | 145 | 52860 | 131836 | 90443606 |
| Skin discolouration | 23.53 | 9.84 | 68 | 52937 | 44247 | 90531195 |
| Lung disorder | 23.44 | 9.84 | 32 | 52973 | 149851 | 90425591 |
| Pneumonia | 23.29 | 9.84 | 512 | 52493 | 637547 | 89937895 |
| Sleep disorder | 23.03 | 9.84 | 51 | 52954 | 197979 | 90377463 |
| Thrombosis | 21.95 | 9.84 | 93 | 52912 | 73158 | 90502284 |
| Peripheral venous disease | 21.64 | 9.84 | 11 | 52994 | 83910 | 90491532 |
| Hypervolaemia | 21.13 | 9.84 | 54 | 52951 | 32703 | 90542739 |
| Red blood cell sedimentation rate increased | 21.04 | 9.84 | 11 | 52994 | 82584 | 90492858 |
| Cyst | 20.96 | 9.84 | 36 | 52969 | 16525 | 90558917 |
| Dyspnoea | 20.91 | 9.84 | 668 | 52337 | 880287 | 89695155 |
| Tooth disorder | 20.83 | 9.84 | 52 | 52953 | 31038 | 90544404 |
| Dizziness postural | 20.68 | 9.84 | 26 | 52979 | 9027 | 90566415 |
| Eye swelling | 20.59 | 9.84 | 50 | 52955 | 29336 | 90546106 |
| Blood potassium decreased | 20.48 | 9.84 | 68 | 52937 | 47659 | 90527783 |
| Hypersensitivity | 20.40 | 9.84 | 169 | 52836 | 454508 | 90120934 |
| Dislocation of vertebra | 20.33 | 9.84 | 4 | 53001 | 55964 | 90519478 |
| White blood cell count decreased | 20.25 | 9.84 | 167 | 52838 | 166942 | 90408500 |
| Balance disorder | 20.22 | 9.84 | 111 | 52894 | 96969 | 90478473 |
| Drug hypersensitivity | 20.20 | 9.84 | 382 | 52623 | 463227 | 90112215 |
| Laboratory test abnormal | 20.11 | 9.84 | 62 | 52943 | 41792 | 90533650 |
| Blood cholesterol increased | 20.00 | 9.84 | 59 | 52946 | 207953 | 90367489 |
| Autoimmune disorder | 19.88 | 9.84 | 10 | 52995 | 76734 | 90498708 |
| Bursitis | 19.70 | 9.84 | 29 | 52976 | 131625 | 90443817 |
| Live birth | 19.48 | 9.84 | 11 | 52994 | 79096 | 90496346 |
| Multiple sclerosis relapse | 19.39 | 9.84 | 71 | 52934 | 52234 | 90523208 |
| Dysgeusia | 19.19 | 9.84 | 71 | 52934 | 52489 | 90522953 |
| Rhinorrhoea | 19.08 | 9.84 | 102 | 52903 | 88214 | 90487228 |
| International normalised ratio increased | 19.05 | 9.84 | 66 | 52939 | 47250 | 90528192 |
| Sinoatrial block | 18.93 | 9.84 | 10 | 52995 | 995 | 90574447 |
| Dyspnoea exertional | 18.81 | 9.84 | 88 | 52917 | 72200 | 90503242 |
| Vaginal haemorrhage | 18.58 | 9.84 | 50 | 52955 | 31221 | 90544221 |
| Bone pain | 18.03 | 9.84 | 78 | 52927 | 61905 | 90513537 |
| Vision blurred | 17.80 | 9.84 | 118 | 52887 | 110175 | 90465267 |
| Cardiac disorder | 16.88 | 9.84 | 72 | 52933 | 56800 | 90518642 |
| Product complaint | 16.63 | 9.84 | 29 | 52976 | 13471 | 90561971 |
| Dry skin | 16.56 | 9.84 | 98 | 52907 | 87975 | 90487467 |
| Pain in extremity | 16.56 | 9.84 | 362 | 52643 | 450167 | 90125275 |
| Lethargy | 16.53 | 9.84 | 77 | 52928 | 63062 | 90512380 |
| Infection | 16.50 | 9.84 | 134 | 52871 | 361960 | 90213482 |
| Influenza | 15.72 | 9.84 | 137 | 52868 | 139127 | 90436315 |
| Overdose | 15.69 | 9.84 | 44 | 52961 | 157665 | 90417777 |
| Burning sensation | 15.60 | 9.84 | 76 | 52929 | 63376 | 90512066 |
| Bronchitis | 15.51 | 9.84 | 147 | 52858 | 152780 | 90422662 |
| Hypertension | 15.51 | 9.84 | 182 | 52823 | 457350 | 90118092 |
| Drug-induced liver injury | 15.46 | 9.84 | 18 | 52987 | 90300 | 90485142 |
| Asthma | 15.40 | 9.84 | 81 | 52924 | 242079 | 90333363 |
| Fluid retention | 15.29 | 9.84 | 96 | 52909 | 87995 | 90487447 |
| Pigmentation disorder | 15.07 | 9.84 | 18 | 52987 | 5931 | 90569511 |
| Hypoacusis | 15.04 | 9.84 | 43 | 52962 | 27807 | 90547635 |
| Injection site mass | 14.86 | 9.84 | 37 | 52968 | 22053 | 90553389 |
| Intentional overdose | 14.70 | 9.84 | 20 | 52985 | 93814 | 90481628 |
| Pulmonary arterial hypertension | 14.69 | 9.84 | 41 | 52964 | 26146 | 90549296 |
| Coeliac disease | 14.59 | 9.84 | 4 | 53001 | 44606 | 90530836 |
| Depression | 14.59 | 9.84 | 252 | 52753 | 300349 | 90275093 |
| Injection site reaction | 14.54 | 9.84 | 98 | 52907 | 91982 | 90483460 |
| Hypophagia | 14.36 | 9.84 | 50 | 52955 | 35887 | 90539555 |
| Pulmonary hypertension | 14.33 | 9.84 | 56 | 52949 | 42467 | 90532975 |
| Ageusia | 14.21 | 9.84 | 30 | 52975 | 16046 | 90559396 |
| Gallbladder disorder | 14.20 | 9.84 | 34 | 52971 | 19769 | 90555673 |
| Platelet count decreased | 14.06 | 9.84 | 132 | 52873 | 136837 | 90438605 |
| Cough | 14.04 | 9.84 | 298 | 52707 | 368664 | 90206778 |
| Nocturia | 13.92 | 9.84 | 23 | 52982 | 10232 | 90565210 |
| Oedema peripheral | 13.91 | 9.84 | 220 | 52785 | 257695 | 90317747 |
| Hypoxia | 13.90 | 9.84 | 81 | 52924 | 72318 | 90503124 |
| Adverse event | 13.84 | 9.84 | 30 | 52975 | 117388 | 90458054 |
| Adjustment disorder with depressed mood | 13.82 | 9.84 | 8 | 52997 | 56745 | 90518697 |
| Cellulitis | 13.71 | 9.84 | 96 | 52909 | 91241 | 90484201 |
| Small intestinal obstruction | 13.69 | 9.84 | 35 | 52970 | 21199 | 90554243 |
| Hepatic function abnormal | 13.63 | 9.84 | 5 | 53000 | 46283 | 90529159 |
| Inflammation | 13.57 | 9.84 | 56 | 52949 | 178536 | 90396906 |
| Blood glucose decreased | 13.46 | 9.84 | 37 | 52968 | 23392 | 90552050 |
| Nail disorder | 13.45 | 9.84 | 9 | 52996 | 59058 | 90516384 |
| Blepharospasm | 13.24 | 9.84 | 8 | 52997 | 55437 | 90520005 |
| X-ray abnormal | 13.22 | 9.84 | 5 | 53000 | 45419 | 90530023 |
| Multiple sclerosis | 13.15 | 9.84 | 41 | 52964 | 27799 | 90547643 |
| Multiple allergies | 13.09 | 9.84 | 28 | 52977 | 15118 | 90560324 |
| Aspartate aminotransferase increased | 13.07 | 9.84 | 104 | 52901 | 102833 | 90472609 |
| Pleural effusion | 13.07 | 9.84 | 111 | 52894 | 111880 | 90463562 |
| Anxiety | 13.05 | 9.84 | 254 | 52751 | 309518 | 90265924 |
| Pain in jaw | 12.91 | 9.84 | 59 | 52946 | 47926 | 90527516 |
| Sleep disorder due to a general medical condition | 12.90 | 9.84 | 5 | 53000 | 44733 | 90530709 |
| Administration site swelling | 12.84 | 9.84 | 9 | 52996 | 1490 | 90573952 |
| Plasma cell myeloma recurrent | 12.75 | 9.84 | 14 | 52991 | 4214 | 90571228 |
| Cerebrovascular accident | 12.65 | 9.84 | 119 | 52886 | 123414 | 90452028 |
| Dry eye | 12.57 | 9.84 | 67 | 52938 | 57864 | 90517578 |
| Gait disturbance | 12.50 | 9.84 | 218 | 52787 | 260278 | 90315164 |
| Musculoskeletal stiffness | 12.49 | 9.84 | 112 | 52893 | 296420 | 90279022 |
| Restless legs syndrome | 12.43 | 9.84 | 35 | 52970 | 22435 | 90553007 |
| Chest pain | 12.43 | 9.84 | 259 | 52746 | 319386 | 90256056 |
| Pollakiuria | 12.40 | 9.84 | 45 | 52960 | 32960 | 90542482 |
| Upper limb fracture | 12.32 | 9.84 | 34 | 52971 | 21544 | 90553898 |
| Confusional state | 12.18 | 9.84 | 156 | 52849 | 386049 | 90189393 |
| Hospice care | 12.15 | 9.84 | 21 | 52984 | 9683 | 90565759 |
| Rotator cuff syndrome | 12.14 | 9.84 | 28 | 52977 | 15891 | 90559551 |
| Eustachian tube obstruction | 11.82 | 9.84 | 3 | 53002 | 34 | 90575408 |
| Lupus-like syndrome | 11.73 | 9.84 | 7 | 52998 | 48839 | 90526603 |
| Agranulocytosis | 11.71 | 9.84 | 3 | 53002 | 34999 | 90540443 |
| Haematocrit decreased | 11.68 | 9.84 | 52 | 52953 | 41780 | 90533662 |
| Chest discomfort | 11.64 | 9.84 | 128 | 52877 | 138237 | 90437205 |
| International normalised ratio decreased | 11.48 | 9.84 | 14 | 52991 | 4710 | 90570732 |
| Blood triglycerides increased | 11.39 | 9.84 | 25 | 52980 | 13736 | 90561706 |
| Intestinal dilatation | 11.37 | 9.84 | 10 | 52995 | 2300 | 90573142 |
| Very low density lipoprotein increased | 11.34 | 9.84 | 4 | 53001 | 147 | 90575295 |
| Endometriosis | 11.28 | 9.84 | 16 | 52989 | 6232 | 90569210 |
| Febrile neutropenia | 11.20 | 9.84 | 51 | 52954 | 158298 | 90417144 |
| Blood potassium increased | 11.17 | 9.84 | 32 | 52973 | 20717 | 90554725 |
| Coronary artery disease | 11.11 | 9.84 | 44 | 52961 | 33579 | 90541863 |
| Therapeutic response unexpected | 11.06 | 9.84 | 33 | 52972 | 21847 | 90553595 |
| Insomnia | 11.01 | 9.84 | 264 | 52741 | 333210 | 90242232 |
| Cold sweat | 11.00 | 9.84 | 25 | 52980 | 14056 | 90561386 |
| Scratch | 10.63 | 9.84 | 20 | 52985 | 9846 | 90565596 |
| Psoriatic arthropathy | 10.62 | 9.84 | 84 | 52921 | 228251 | 90347191 |
| Cardiac pacemaker insertion | 10.61 | 9.84 | 13 | 52992 | 4394 | 90571048 |
| Laryngeal pain | 10.58 | 9.84 | 13 | 52992 | 4409 | 90571033 |
| Meniscus injury | 10.55 | 9.84 | 18 | 52987 | 8219 | 90567223 |
| Haematoma | 10.50 | 9.84 | 48 | 52957 | 39000 | 90536442 |
| Complication associated with device | 10.47 | 9.84 | 30 | 52975 | 19419 | 90556023 |
| Cholecystectomy | 10.47 | 9.84 | 22 | 52983 | 11733 | 90563709 |
| Heavy menstrual bleeding | 10.41 | 9.84 | 31 | 52974 | 20499 | 90554943 |
| Blood glucose increased | 10.38 | 9.84 | 93 | 52912 | 95153 | 90480289 |
| Anaemia | 10.38 | 9.84 | 275 | 52730 | 352527 | 90222915 |
| Pulmonary oedema | 10.37 | 9.84 | 67 | 52938 | 62013 | 90513429 |
| Interstitial lung disease | 10.33 | 9.84 | 18 | 52987 | 76387 | 90499055 |
| Adverse drug reaction | 10.29 | 9.84 | 109 | 52896 | 116592 | 90458850 |
| Pulse absent | 10.20 | 9.84 | 15 | 52990 | 6040 | 90569402 |
| Chronic kidney disease | 10.19 | 9.84 | 57 | 52948 | 50134 | 90525308 |
| Breast cancer stage II | 10.10 | 9.84 | 4 | 53001 | 35330 | 90540112 |
| Osteopenia | 10.07 | 9.84 | 33 | 52972 | 22969 | 90552473 |
| Night sweats | 10.01 | 9.84 | 40 | 52965 | 128726 | 90446716 |
| Stress fracture | 9.97 | 9.84 | 18 | 52987 | 8593 | 90566849 |
| Injury | 9.94 | 9.84 | 71 | 52934 | 197278 | 90378164 |
| Rib fracture | 9.89 | 9.84 | 36 | 52969 | 26399 | 90549043 |
| Rash pruritic | 9.86 | 9.84 | 82 | 52923 | 82132 | 90493310 |
| Liver disorder | 9.86 | 9.84 | 37 | 52968 | 121232 | 90454210 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 171.34 | 11.57 | 175 | 36042 | 638160 | 41946958 |
| Product use in unapproved indication | 100.05 | 11.57 | 18 | 36199 | 184438 | 42400680 |
| Drug abuse | 72.72 | 11.57 | 4 | 36213 | 104767 | 42480351 |
| Flushing | 69.54 | 11.57 | 118 | 36099 | 36910 | 42548208 |
| Fatigue | 61.17 | 11.57 | 601 | 35616 | 435040 | 42150078 |
| Asthenia | 53.17 | 11.57 | 414 | 35803 | 280379 | 42304739 |
| Plasma cell myeloma | 51.07 | 11.57 | 120 | 36097 | 47458 | 42537660 |
| Diarrhoea | 50.85 | 11.57 | 606 | 35611 | 460243 | 42124875 |
| Toxicity to various agents | 47.40 | 11.57 | 76 | 36141 | 229060 | 42356058 |
| Product dose omission issue | 45.90 | 11.57 | 255 | 35962 | 154110 | 42431008 |
| General physical health deterioration | 44.33 | 11.57 | 38 | 36179 | 151208 | 42433910 |
| Dizziness | 42.54 | 11.57 | 359 | 35858 | 248895 | 42336223 |
| Completed suicide | 39.89 | 11.57 | 16 | 36201 | 96449 | 42488669 |
| Myalgia | 39.43 | 11.57 | 174 | 36043 | 95906 | 42489212 |
| Laboratory test abnormal | 38.94 | 11.57 | 70 | 36147 | 22908 | 42562210 |
| Full blood count decreased | 35.30 | 11.57 | 63 | 36154 | 20497 | 42564621 |
| Fall | 34.95 | 11.57 | 328 | 35889 | 234192 | 42350926 |
| Muscle spasms | 33.18 | 11.57 | 153 | 36064 | 85891 | 42499227 |
| Febrile neutropenia | 31.83 | 11.57 | 69 | 36148 | 185634 | 42399484 |
| Drug interaction | 31.25 | 11.57 | 119 | 36098 | 266880 | 42318238 |
| Drug hypersensitivity | 30.05 | 11.57 | 165 | 36052 | 99224 | 42485894 |
| Intentional product use issue | 27.97 | 11.57 | 13 | 36204 | 71820 | 42513298 |
| Cytokine release syndrome | 27.25 | 11.57 | 3 | 36214 | 44524 | 42540594 |
| COVID-19 | 26.34 | 11.57 | 36 | 36181 | 115912 | 42469206 |
| Intentional overdose | 25.83 | 11.57 | 6 | 36211 | 51450 | 42533668 |
| Blood testosterone decreased | 25.79 | 11.57 | 26 | 36191 | 4876 | 42580242 |
| White blood cell count decreased | 25.56 | 11.57 | 171 | 36046 | 110225 | 42474893 |
| Psoriasis | 25.48 | 11.57 | 95 | 36122 | 48509 | 42536609 |
| Treatment failure | 24.90 | 11.57 | 11 | 36206 | 62613 | 42522505 |
| Adverse drug reaction | 23.80 | 11.57 | 78 | 36139 | 37356 | 42547762 |
| Gastrointestinal haemorrhage | 23.61 | 11.57 | 153 | 36064 | 97573 | 42487545 |
| Myocardial infarction | 23.47 | 11.57 | 183 | 36034 | 123826 | 42461292 |
| Drug ineffective | 23.45 | 11.57 | 386 | 35831 | 629811 | 41955307 |
| Hypoaesthesia | 23.20 | 11.57 | 121 | 36096 | 71342 | 42513776 |
| Sinusitis | 22.79 | 11.57 | 90 | 36127 | 47202 | 42537916 |
| Interstitial lung disease | 22.62 | 11.57 | 20 | 36197 | 78442 | 42506676 |
| Cardiac disorder | 21.89 | 11.57 | 91 | 36126 | 48841 | 42536277 |
| Product use issue | 21.61 | 11.57 | 20 | 36197 | 76731 | 42508387 |
| Mental status changes | 20.98 | 11.57 | 81 | 36136 | 42034 | 42543084 |
| Meningitis cryptococcal | 20.25 | 11.57 | 19 | 36198 | 3264 | 42581854 |
| Multiple organ dysfunction syndrome | 20.20 | 11.57 | 32 | 36185 | 97003 | 42488115 |
| Myelosuppression | 19.75 | 11.57 | 5 | 36212 | 40456 | 42544662 |
| Condition aggravated | 19.29 | 11.57 | 136 | 36081 | 260618 | 42324500 |
| Therapy cessation | 19.19 | 11.57 | 49 | 36168 | 20401 | 42564717 |
| Memory impairment | 19.12 | 11.57 | 89 | 36128 | 50133 | 42534985 |
| Hepatic function abnormal | 19.06 | 11.57 | 10 | 36207 | 51557 | 42533561 |
| Haemoglobin decreased | 19.05 | 11.57 | 184 | 36033 | 132287 | 42452831 |
| Coma | 18.90 | 11.57 | 11 | 36206 | 53543 | 42531575 |
| Drug ineffective for unapproved indication | 18.52 | 11.57 | 8 | 36209 | 46155 | 42538963 |
| Dehydration | 18.51 | 11.57 | 193 | 36024 | 141574 | 42443544 |
| Flatulence | 18.38 | 11.57 | 55 | 36162 | 25097 | 42560021 |
| Cerebrovascular accident | 17.62 | 11.57 | 142 | 36075 | 97018 | 42488100 |
| Drug resistance | 17.17 | 11.57 | 4 | 36213 | 34244 | 42550874 |
| Suicide attempt | 16.95 | 11.57 | 9 | 36208 | 46091 | 42539027 |
| Muscular weakness | 16.78 | 11.57 | 125 | 36092 | 83373 | 42501745 |
| Atelectasis | 16.74 | 11.57 | 45 | 36172 | 19316 | 42565802 |
| Coronary artery occlusion | 16.74 | 11.57 | 32 | 36185 | 10965 | 42574153 |
| Feeling abnormal | 16.69 | 11.57 | 109 | 36108 | 69677 | 42515441 |
| Cardiac failure congestive | 16.56 | 11.57 | 127 | 36090 | 85475 | 42499643 |
| Agranulocytosis | 16.54 | 11.57 | 3 | 36214 | 30609 | 42554509 |
| Viral infection | 16.27 | 11.57 | 49 | 36168 | 22434 | 42562684 |
| Leukopenia | 16.18 | 11.57 | 24 | 36193 | 74722 | 42510396 |
| Transaminases abnormal | 16.09 | 11.57 | 7 | 36210 | 309 | 42584809 |
| Rash | 16.02 | 11.57 | 327 | 35890 | 276627 | 42308491 |
| Fluid retention | 15.90 | 11.57 | 61 | 36156 | 31558 | 42553560 |
| Oedema peripheral | 15.80 | 11.57 | 181 | 36036 | 135895 | 42449223 |
| High density lipoprotein decreased | 15.79 | 11.57 | 18 | 36199 | 3879 | 42581239 |
| Weight decreased | 15.69 | 11.57 | 256 | 35961 | 207692 | 42377426 |
| Cardiac failure | 15.69 | 11.57 | 43 | 36174 | 106813 | 42478305 |
| Constipation | 15.46 | 11.57 | 208 | 36009 | 162083 | 42423035 |
| Influenza | 15.41 | 11.57 | 98 | 36119 | 62077 | 42523041 |
| Renal impairment | 14.99 | 11.57 | 46 | 36171 | 110182 | 42474936 |
| Cerebral small vessel ischaemic disease | 14.97 | 11.57 | 8 | 36209 | 558 | 42584560 |
| Nausea | 14.44 | 11.57 | 440 | 35777 | 396359 | 42188759 |
| Muscle fatigue | 14.42 | 11.57 | 12 | 36205 | 1759 | 42583359 |
| Neuropathy peripheral | 14.41 | 11.57 | 141 | 36076 | 101712 | 42483406 |
| Increased tendency to bruise | 14.13 | 11.57 | 18 | 36199 | 4352 | 42580766 |
| Dyspepsia | 14.10 | 11.57 | 71 | 36146 | 41281 | 42543837 |
| Unevaluable event | 13.97 | 11.57 | 62 | 36155 | 34226 | 42550892 |
| International normalised ratio increased | 13.90 | 11.57 | 79 | 36138 | 48089 | 42537029 |
| Altered state of consciousness | 13.56 | 11.57 | 4 | 36213 | 29255 | 42555863 |
| Influenza like illness | 13.30 | 11.57 | 58 | 36159 | 31782 | 42553336 |
| Headache | 13.30 | 11.57 | 281 | 35936 | 239088 | 42346030 |
| Back pain | 13.20 | 11.57 | 181 | 36036 | 141595 | 42443523 |
| Coronary artery disease | 12.90 | 11.57 | 84 | 36133 | 53636 | 42531482 |
| Cholestasis | 12.72 | 11.57 | 6 | 36211 | 32873 | 42552245 |
| Haematocrit decreased | 12.66 | 11.57 | 61 | 36156 | 34847 | 42550271 |
| Paraesthesia | 12.58 | 11.57 | 106 | 36111 | 73353 | 42511765 |
| Contraindicated product administered | 12.58 | 11.57 | 3 | 36214 | 25269 | 42559849 |
| Foetal exposure during pregnancy | 12.54 | 11.57 | 13 | 36204 | 47298 | 42537820 |
| C-reactive protein increased | 12.27 | 11.57 | 22 | 36195 | 63538 | 42521580 |
| Cellulitis | 12.26 | 11.57 | 92 | 36125 | 61493 | 42523625 |
| Obstructive airways disorder | 12.20 | 11.57 | 3 | 36214 | 24756 | 42560362 |
| Small intestinal obstruction | 12.17 | 11.57 | 37 | 36180 | 17024 | 42568094 |
| Gait disturbance | 12.11 | 11.57 | 132 | 36085 | 97868 | 42487250 |
| Bronchitis | 12.07 | 11.57 | 75 | 36142 | 47126 | 42537992 |
| Pneumonia | 12.03 | 11.57 | 455 | 35762 | 421694 | 42163424 |
| Application site exfoliation | 12.01 | 11.57 | 5 | 36212 | 198 | 42584920 |
| Blood glucose increased | 11.91 | 11.57 | 105 | 36112 | 73594 | 42511524 |
| Drug reaction with eosinophilia and systemic symptoms | 11.80 | 11.57 | 11 | 36206 | 42064 | 42543054 |
| Therapeutic product effect incomplete | 11.61 | 11.57 | 27 | 36190 | 70912 | 42514206 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 228.24 | 9.78 | 374 | 69475 | 1499811 | 109019639 |
| Product use in unapproved indication | 166.76 | 9.78 | 39 | 69810 | 447338 | 110072112 |
| Synovitis | 143.86 | 9.78 | 7 | 69842 | 274085 | 110245365 |
| Product dose omission issue | 117.82 | 9.78 | 458 | 69391 | 321324 | 110198126 |
| Hand deformity | 116.55 | 9.78 | 5 | 69844 | 218501 | 110300949 |
| Contraindicated product administered | 111.59 | 9.78 | 13 | 69836 | 248254 | 110271196 |
| Pemphigus | 105.00 | 9.78 | 8 | 69841 | 214562 | 110304888 |
| Fall | 104.35 | 9.78 | 695 | 69154 | 602787 | 109916663 |
| Systemic lupus erythematosus | 103.39 | 9.78 | 18 | 69831 | 254320 | 110265130 |
| Treatment failure | 101.60 | 9.78 | 25 | 69824 | 277209 | 110242241 |
| Infusion related reaction | 100.43 | 9.78 | 58 | 69791 | 381104 | 110138346 |
| Completed suicide | 98.86 | 9.78 | 17 | 69832 | 242364 | 110277086 |
| Anti-cyclic citrullinated peptide antibody positive | 97.60 | 9.78 | 4 | 69845 | 181980 | 110337470 |
| Drug abuse | 94.81 | 9.78 | 4 | 69845 | 177407 | 110342043 |
| General physical health deterioration | 90.77 | 9.78 | 81 | 69768 | 425214 | 110094236 |
| Glossodynia | 89.60 | 9.78 | 16 | 69833 | 221988 | 110297462 |
| Drug intolerance | 81.38 | 9.78 | 82 | 69767 | 406430 | 110113020 |
| Dizziness | 81.06 | 9.78 | 733 | 69116 | 697460 | 109821990 |
| Duodenal ulcer perforation | 80.60 | 9.78 | 9 | 69840 | 177691 | 110341759 |
| Pericarditis | 79.81 | 9.78 | 20 | 69829 | 219094 | 110300356 |
| Helicobacter infection | 78.15 | 9.78 | 11 | 69838 | 181866 | 110337584 |
| Lower respiratory tract infection | 74.67 | 9.78 | 30 | 69819 | 243076 | 110276374 |
| Therapy cessation | 73.10 | 9.78 | 114 | 69735 | 44743 | 110474707 |
| Diarrhoea | 71.34 | 9.78 | 1061 | 68788 | 1138444 | 109381006 |
| Toxicity to various agents | 70.56 | 9.78 | 122 | 69727 | 480433 | 110039017 |
| C-reactive protein abnormal | 69.04 | 9.78 | 3 | 69846 | 129692 | 110389758 |
| Folliculitis | 67.82 | 9.78 | 12 | 69837 | 167641 | 110351809 |
| Rheumatoid factor positive | 67.05 | 9.78 | 4 | 69845 | 131636 | 110387814 |
| Product use issue | 66.91 | 9.78 | 59 | 69790 | 311636 | 110207814 |
| Myalgia | 66.79 | 9.78 | 298 | 69551 | 222083 | 110297367 |
| Fatigue | 65.83 | 9.78 | 1105 | 68744 | 1214853 | 109304597 |
| Device expulsion | 65.62 | 9.78 | 89 | 69760 | 30802 | 110488648 |
| Plasma cell myeloma | 65.04 | 9.78 | 131 | 69718 | 62805 | 110456645 |
| Maternal exposure during pregnancy | 64.01 | 9.78 | 41 | 69808 | 254842 | 110264608 |
| Flushing | 62.46 | 9.78 | 176 | 69673 | 104560 | 110414890 |
| Intentional product use issue | 62.09 | 9.78 | 40 | 69809 | 247866 | 110271584 |
| Muscle injury | 61.71 | 9.78 | 8 | 69841 | 140799 | 110378651 |
| Cardiac failure congestive | 60.21 | 9.78 | 221 | 69628 | 150779 | 110368671 |
| C-reactive protein increased | 59.03 | 9.78 | 32 | 69817 | 217887 | 110301563 |
| Dehydration | 58.91 | 9.78 | 339 | 69510 | 279172 | 110240278 |
| Rheumatic fever | 58.76 | 9.78 | 5 | 69844 | 122574 | 110396876 |
| Asthenia | 57.78 | 9.78 | 677 | 69172 | 688322 | 109831128 |
| Wound | 55.80 | 9.78 | 40 | 69809 | 234397 | 110285053 |
| Deep vein thrombosis | 55.15 | 9.78 | 204 | 69645 | 139683 | 110379767 |
| Drug ineffective | 54.62 | 9.78 | 657 | 69192 | 1519883 | 108999567 |
| Irritable bowel syndrome | 52.52 | 9.78 | 19 | 69830 | 164196 | 110355254 |
| Therapeutic product effect incomplete | 50.93 | 9.78 | 40 | 69809 | 223765 | 110295685 |
| Haemoglobin decreased | 50.67 | 9.78 | 299 | 69550 | 248428 | 110271022 |
| Feeling abnormal | 50.41 | 9.78 | 237 | 69612 | 180474 | 110338976 |
| Sleep disorder due to general medical condition, insomnia type | 48.80 | 9.78 | 5 | 69844 | 105638 | 110413812 |
| Fibromyalgia | 47.91 | 9.78 | 24 | 69825 | 170885 | 110348565 |
| Full blood count decreased | 46.05 | 9.78 | 77 | 69772 | 32022 | 110487428 |
| Hepatic enzyme increased | 45.68 | 9.78 | 83 | 69766 | 320809 | 110198641 |
| Liver injury | 45.46 | 9.78 | 19 | 69830 | 150394 | 110369056 |
| Myelosuppression | 44.80 | 9.78 | 4 | 69845 | 94336 | 110425114 |
| COVID-19 | 43.99 | 9.78 | 54 | 69795 | 245006 | 110274444 |
| Unevaluable event | 41.85 | 9.78 | 106 | 69743 | 59121 | 110460329 |
| Joint swelling | 41.58 | 9.78 | 142 | 69707 | 442703 | 110076747 |
| Facet joint syndrome | 41.25 | 9.78 | 6 | 69843 | 96822 | 110422628 |
| Ill-defined disorder | 41.08 | 9.78 | 24 | 69825 | 156829 | 110362621 |
| Lip dry | 40.83 | 9.78 | 7 | 69842 | 100076 | 110419374 |
| International normalised ratio increased | 40.65 | 9.78 | 134 | 69715 | 86638 | 110432812 |
| Type 2 diabetes mellitus | 39.92 | 9.78 | 32 | 69817 | 177200 | 110342250 |
| Muscle spasms | 39.60 | 9.78 | 306 | 69543 | 277851 | 110241599 |
| Nausea | 38.08 | 9.78 | 1035 | 68814 | 1234655 | 109284795 |
| Arthropathy | 36.09 | 9.78 | 80 | 69769 | 287442 | 110232008 |
| Mental status changes | 36.06 | 9.78 | 118 | 69731 | 76004 | 110443446 |
| Dyspnoea exertional | 35.50 | 9.78 | 145 | 69704 | 103915 | 110415535 |
| Dyspnoea | 34.90 | 9.78 | 930 | 68919 | 1105942 | 109413508 |
| Urticaria thermal | 34.88 | 9.78 | 13 | 69836 | 518 | 110518932 |
| Back pain | 34.86 | 9.78 | 373 | 69476 | 370623 | 110148827 |
| Hypervolaemia | 34.40 | 9.78 | 88 | 69761 | 49372 | 110470078 |
| Fluid retention | 34.25 | 9.78 | 134 | 69715 | 94173 | 110425277 |
| Myocardial infarction | 34.14 | 9.78 | 223 | 69626 | 191860 | 110327590 |
| Swollen joint count increased | 33.80 | 9.78 | 6 | 69843 | 83655 | 110435795 |
| Administration site erythema | 33.49 | 9.78 | 12 | 69837 | 427 | 110519023 |
| Epilepsy | 33.06 | 9.78 | 11 | 69838 | 100198 | 110419252 |
| Device dislocation | 32.76 | 9.78 | 66 | 69783 | 31638 | 110487812 |
| Impaired healing | 32.58 | 9.78 | 46 | 69803 | 196671 | 110322779 |
| Gastrointestinal haemorrhage | 32.43 | 9.78 | 197 | 69652 | 165321 | 110354129 |
| Condition aggravated | 32.11 | 9.78 | 303 | 69546 | 734533 | 109784917 |
| Blister | 31.30 | 9.78 | 60 | 69789 | 227316 | 110292134 |
| Wheezing | 31.23 | 9.78 | 72 | 69777 | 255158 | 110264292 |
| Discoloured vomit | 30.94 | 9.78 | 18 | 69831 | 1999 | 110517451 |
| Obesity | 30.17 | 9.78 | 17 | 69832 | 113334 | 110406116 |
| Mobility decreased | 29.84 | 9.78 | 66 | 69783 | 237356 | 110282094 |
| Nasal congestion | 29.70 | 9.78 | 132 | 69717 | 98150 | 110421300 |
| Stomatitis | 29.37 | 9.78 | 81 | 69768 | 270161 | 110249289 |
| Cerebrovascular accident | 28.96 | 9.78 | 205 | 69644 | 181079 | 110338371 |
| Flatulence | 28.54 | 9.78 | 85 | 69764 | 52064 | 110467386 |
| Cytokine release syndrome | 28.50 | 9.78 | 5 | 69844 | 70301 | 110449149 |
| Rheumatoid arthritis | 28.15 | 9.78 | 96 | 69753 | 299517 | 110219933 |
| Tremor | 27.95 | 9.78 | 221 | 69628 | 202011 | 110317439 |
| Multiple sclerosis relapse | 27.60 | 9.78 | 82 | 69767 | 50158 | 110469292 |
| Discomfort | 27.55 | 9.78 | 59 | 69790 | 214648 | 110304802 |
| Cardiac disorder | 27.38 | 9.78 | 108 | 69741 | 76172 | 110443278 |
| Blood triglycerides increased | 27.38 | 9.78 | 52 | 69797 | 23874 | 110495576 |
| Intentional overdose | 27.32 | 9.78 | 26 | 69823 | 132475 | 110386975 |
| Pneumonia | 27.11 | 9.78 | 735 | 69114 | 875979 | 109643471 |
| Gastrointestinal disorder | 26.68 | 9.78 | 72 | 69777 | 241880 | 110277570 |
| Hypercholesterolaemia | 26.61 | 9.78 | 12 | 69837 | 90825 | 110428625 |
| Haematocrit decreased | 26.53 | 9.78 | 97 | 69752 | 66020 | 110453430 |
| Peripheral venous disease | 26.44 | 9.78 | 10 | 69839 | 84107 | 110435343 |
| Bursitis | 26.20 | 9.78 | 26 | 69823 | 129892 | 110389558 |
| Chills | 26.19 | 9.78 | 208 | 69641 | 190372 | 110329078 |
| Grip strength decreased | 26.10 | 9.78 | 9 | 69840 | 80165 | 110439285 |
| Hip fracture | 25.97 | 9.78 | 64 | 69785 | 35087 | 110484363 |
| Blood glucose increased | 25.51 | 9.78 | 157 | 69692 | 132339 | 110387111 |
| Alopecia | 25.50 | 9.78 | 131 | 69718 | 364622 | 110154828 |
| Injection site haemorrhage | 25.33 | 9.78 | 61 | 69788 | 32967 | 110486483 |
| Femoral artery dissection | 25.28 | 9.78 | 6 | 69843 | 46 | 110519404 |
| Therapeutic product effect decreased | 25.25 | 9.78 | 75 | 69774 | 244241 | 110275209 |
| Dysgeusia | 25.05 | 9.78 | 99 | 69750 | 69886 | 110449564 |
| Injection site pain | 24.90 | 9.78 | 195 | 69654 | 177727 | 110341723 |
| Influenza like illness | 24.67 | 9.78 | 116 | 69733 | 88296 | 110431154 |
| Internal haemorrhage | 24.46 | 9.78 | 31 | 69818 | 10040 | 110509410 |
| Febrile neutropenia | 24.33 | 9.78 | 110 | 69739 | 316657 | 110202793 |
| Headache | 24.30 | 9.78 | 729 | 69120 | 881648 | 109637802 |
| Pelvic pain | 23.89 | 9.78 | 39 | 69810 | 15903 | 110503547 |
| Coronary artery disease | 23.74 | 9.78 | 99 | 69750 | 71591 | 110447859 |
| Hospice care | 23.60 | 9.78 | 34 | 69815 | 12439 | 110507011 |
| Lung disorder | 23.50 | 9.78 | 49 | 69800 | 179998 | 110339452 |
| Cellulitis | 23.43 | 9.78 | 148 | 69701 | 125868 | 110393582 |
| Bronchitis | 23.03 | 9.78 | 174 | 69675 | 156858 | 110362592 |
| Constipation | 22.95 | 9.78 | 335 | 69514 | 357451 | 110161999 |
| Oedema peripheral | 22.79 | 9.78 | 312 | 69537 | 328348 | 110191102 |
| Joint range of motion decreased | 22.76 | 9.78 | 26 | 69823 | 121806 | 110397644 |
| Urinary tract infection | 22.32 | 9.78 | 309 | 69540 | 325973 | 110193477 |
| Coma | 22.18 | 9.78 | 25 | 69824 | 117844 | 110401606 |
| Injection site bruising | 22.10 | 9.78 | 77 | 69772 | 51186 | 110468264 |
| Small intestinal obstruction | 22.08 | 9.78 | 57 | 69792 | 32156 | 110487294 |
| Nervousness | 22.03 | 9.78 | 62 | 69787 | 36789 | 110482661 |
| Autoimmune disorder | 21.93 | 9.78 | 7 | 69842 | 65476 | 110453974 |
| Agranulocytosis | 21.78 | 9.78 | 6 | 69843 | 61754 | 110457696 |
| Eosinophilia | 21.65 | 9.78 | 5 | 69844 | 57931 | 110461519 |
| Hepatic function abnormal | 21.55 | 9.78 | 15 | 69834 | 89280 | 110430170 |
| Intentional product misuse | 21.10 | 9.78 | 32 | 69817 | 132872 | 110386578 |
| Pulmonary fibrosis | 21.06 | 9.78 | 20 | 69829 | 102022 | 110417428 |
| Wound infection | 20.99 | 9.78 | 18 | 69831 | 96447 | 110423003 |
| Complication associated with device | 20.99 | 9.78 | 42 | 69807 | 20031 | 110499419 |
| Inflammation | 20.93 | 9.78 | 58 | 69791 | 193180 | 110326270 |
| Dizziness postural | 20.89 | 9.78 | 35 | 69814 | 14574 | 110504876 |
| Blood testosterone decreased | 20.77 | 9.78 | 16 | 69833 | 2832 | 110516618 |
| Prescribed overdose | 20.75 | 9.78 | 15 | 69834 | 87566 | 110431884 |
| Interstitial lung disease | 20.75 | 9.78 | 35 | 69814 | 139299 | 110380151 |
| Atrial fibrillation | 20.68 | 9.78 | 229 | 69620 | 229413 | 110290037 |
| Drug interaction | 20.65 | 9.78 | 209 | 69640 | 499974 | 110019476 |
| Chest pain | 20.56 | 9.78 | 343 | 69506 | 376032 | 110143418 |
| Blood potassium decreased | 20.55 | 9.78 | 78 | 69771 | 54036 | 110465414 |
| Drug ineffective for unapproved indication | 20.26 | 9.78 | 21 | 69828 | 102817 | 110416633 |
| Coronary artery occlusion | 20.22 | 9.78 | 36 | 69813 | 15736 | 110503714 |
| Weight decreased | 20.15 | 9.78 | 411 | 69438 | 467646 | 110051804 |
| Blood glucose decreased | 20.02 | 9.78 | 52 | 69797 | 29436 | 110490014 |
| Hypoacusis | 19.87 | 9.78 | 58 | 69791 | 35133 | 110484317 |
| White blood cell count decreased | 19.86 | 9.78 | 227 | 69622 | 229163 | 110290287 |
| Rotator cuff syndrome | 19.84 | 9.78 | 37 | 69812 | 16757 | 110502693 |
| Asthma | 19.77 | 9.78 | 86 | 69763 | 250205 | 110269245 |
| Injection site erythema | 19.66 | 9.78 | 114 | 69735 | 94062 | 110425388 |
| Aspartate aminotransferase increased | 19.54 | 9.78 | 170 | 69679 | 159766 | 110359684 |
| Influenza | 19.25 | 9.78 | 177 | 69672 | 168924 | 110350526 |
| Thrombosis | 19.20 | 9.78 | 126 | 69723 | 108536 | 110410914 |
| Eye swelling | 19.17 | 9.78 | 55 | 69794 | 32993 | 110486457 |
| Live birth | 19.11 | 9.78 | 10 | 69839 | 69474 | 110449976 |
| Neuropathy peripheral | 19.09 | 9.78 | 185 | 69664 | 179092 | 110340358 |
| Drug resistance | 18.93 | 9.78 | 6 | 69843 | 56368 | 110463082 |
| Viral infection | 18.88 | 9.78 | 75 | 69774 | 53064 | 110466386 |
| Overdose | 18.67 | 9.78 | 80 | 69769 | 233714 | 110285736 |
| Low density lipoprotein increased | 18.63 | 9.78 | 28 | 69821 | 10638 | 110508812 |
| Pulmonary embolism | 18.46 | 9.78 | 212 | 69637 | 214262 | 110305188 |
| Atelectasis | 18.37 | 9.78 | 58 | 69791 | 36654 | 110482796 |
| Exposure during pregnancy | 18.32 | 9.78 | 50 | 69799 | 167374 | 110352076 |
| Product complaint | 18.05 | 9.78 | 32 | 69817 | 13940 | 110505510 |
| Nail disorder | 18.02 | 9.78 | 7 | 69842 | 57928 | 110461522 |
| Dislocation of vertebra | 17.96 | 9.78 | 3 | 69846 | 43718 | 110475732 |
| Sleep disorder | 17.75 | 9.78 | 65 | 69784 | 198579 | 110320871 |
| Hepatocellular injury | 17.71 | 9.78 | 5 | 69844 | 50637 | 110468813 |
| Coeliac disease | 17.66 | 9.78 | 3 | 69846 | 43184 | 110476266 |
| Pleural effusion | 17.29 | 9.78 | 180 | 69669 | 177529 | 110341921 |
| Meningitis cryptococcal | 17.22 | 9.78 | 18 | 69831 | 4744 | 110514706 |
| Platelet count decreased | 16.89 | 9.78 | 221 | 69628 | 230222 | 110289228 |
| Cholestasis | 16.71 | 9.78 | 10 | 69839 | 64508 | 110454942 |
| Occult blood positive | 16.65 | 9.78 | 22 | 69827 | 7423 | 110512027 |
| Hypersensitivity | 16.59 | 9.78 | 169 | 69680 | 403829 | 110115621 |
| Red blood cell sedimentation rate increased | 16.57 | 9.78 | 15 | 69834 | 78287 | 110441163 |
| Blepharospasm | 16.46 | 9.78 | 7 | 69842 | 54844 | 110464606 |
| Infection | 16.36 | 9.78 | 148 | 69701 | 362052 | 110157398 |
| Pain in extremity | 16.35 | 9.78 | 413 | 69436 | 486705 | 110032745 |
| Acute respiratory failure | 16.30 | 9.78 | 92 | 69757 | 75168 | 110444282 |
| Altered state of consciousness | 16.28 | 9.78 | 8 | 69841 | 57618 | 110461832 |
| Lethargy | 16.23 | 9.78 | 108 | 69741 | 93468 | 110425982 |
| Gait disturbance | 16.10 | 9.78 | 256 | 69593 | 277952 | 110241498 |
| Swelling | 16.05 | 9.78 | 143 | 69706 | 350898 | 110168552 |
| Muscle fatigue | 16.04 | 9.78 | 16 | 69833 | 3991 | 110515459 |
| Pulmonary arterial hypertension | 15.88 | 9.78 | 51 | 69798 | 32517 | 110486933 |
| Pulmonary hypertension | 15.81 | 9.78 | 73 | 69776 | 55147 | 110464303 |
| Pain in jaw | 15.66 | 9.78 | 69 | 69780 | 51108 | 110468342 |
| Bone erosion | 15.45 | 9.78 | 5 | 69844 | 46366 | 110473084 |
| Hypertension | 15.41 | 9.78 | 228 | 69621 | 509856 | 110009594 |
| Depression | 15.11 | 9.78 | 283 | 69566 | 317052 | 110202398 |
| Neurotoxicity | 15.08 | 9.78 | 4 | 69845 | 42203 | 110477247 |
| Transient ischaemic attack | 15.06 | 9.78 | 80 | 69769 | 63902 | 110455548 |
| Haemodialysis | 14.98 | 9.78 | 34 | 69815 | 17685 | 110501765 |
| Hypoxia | 14.96 | 9.78 | 136 | 69713 | 129379 | 110390071 |
| Drug reaction with eosinophilia and systemic symptoms | 14.82 | 9.78 | 18 | 69831 | 82077 | 110437373 |
| Anaphylactic shock | 14.80 | 9.78 | 7 | 69842 | 51539 | 110467911 |
| Sinoatrial block | 14.73 | 9.78 | 10 | 69839 | 1455 | 110517995 |
| Cytomegalovirus infection | 14.73 | 9.78 | 8 | 69841 | 54436 | 110465014 |
| Body height decreased | 14.70 | 9.78 | 25 | 69824 | 10538 | 110508912 |
| Psoriatic arthropathy | 14.70 | 9.78 | 69 | 69780 | 196692 | 110322758 |
| Psoriasis | 14.67 | 9.78 | 144 | 69705 | 139849 | 110379601 |
| Multiple organ dysfunction syndrome | 14.66 | 9.78 | 48 | 69801 | 151662 | 110367788 |
| Liver disorder | 14.45 | 9.78 | 44 | 69805 | 142199 | 110377251 |
| Leukopenia | 14.43 | 9.78 | 47 | 69802 | 148744 | 110370706 |
| Transfusion | 14.40 | 9.78 | 42 | 69807 | 25430 | 110494020 |
| Blood potassium increased | 14.38 | 9.78 | 50 | 69799 | 33199 | 110486251 |
| Myopathy | 13.96 | 9.78 | 41 | 69808 | 24919 | 110494531 |
| Skin laceration | 13.95 | 9.78 | 50 | 69799 | 33703 | 110485747 |
| Hypophagia | 13.92 | 9.78 | 68 | 69781 | 52558 | 110466892 |
| Vaginal haemorrhage | 13.84 | 9.78 | 41 | 69808 | 25033 | 110494417 |
| Hot flush | 13.82 | 9.78 | 80 | 69769 | 65956 | 110453494 |
| Mitral valve repair | 13.80 | 9.78 | 6 | 69843 | 358 | 110519092 |
| Failure to thrive | 13.72 | 9.78 | 28 | 69821 | 13546 | 110505904 |
| Sleep disorder due to a general medical condition | 13.60 | 9.78 | 8 | 69841 | 52104 | 110467346 |
| Eustachian tube obstruction | 13.25 | 9.78 | 4 | 69845 | 82 | 110519368 |
| Vision blurred | 13.17 | 9.78 | 132 | 69717 | 128890 | 110390560 |
| Bone pain | 13.05 | 9.78 | 78 | 69771 | 65055 | 110454395 |
| Transaminases abnormal | 13.03 | 9.78 | 8 | 69841 | 980 | 110518470 |
| Neoplasm progression | 12.94 | 9.78 | 13 | 69836 | 64582 | 110454868 |
| Rash pruritic | 12.90 | 9.78 | 106 | 69743 | 97963 | 110421487 |
| Depressed level of consciousness | 12.68 | 9.78 | 33 | 69816 | 112245 | 110407205 |
| Pericardial haemorrhage | 12.58 | 9.78 | 16 | 69833 | 5201 | 110514249 |
| Radioisotope scan abnormal | 12.44 | 9.78 | 7 | 69842 | 730 | 110518720 |
| Laryngeal pain | 12.36 | 9.78 | 17 | 69832 | 5958 | 110513492 |
| Post procedural haemorrhage | 12.27 | 9.78 | 29 | 69820 | 15483 | 110503967 |
| Rib fracture | 12.27 | 9.78 | 48 | 69801 | 33722 | 110485728 |
| Sinus headache | 12.24 | 9.78 | 17 | 69832 | 6015 | 110513435 |
| Therapeutic response unexpected | 12.24 | 9.78 | 38 | 69811 | 23805 | 110495645 |
| Scratch | 12.21 | 9.78 | 26 | 69823 | 12953 | 110506497 |
| Hepatitis | 12.18 | 9.78 | 24 | 69825 | 90030 | 110429420 |
| Obstructive airways disorder | 12.17 | 9.78 | 7 | 69842 | 46142 | 110473308 |
| Chronic kidney disease | 12.01 | 9.78 | 86 | 69763 | 76205 | 110443245 |
| Red blood cell count decreased | 11.99 | 9.78 | 77 | 69772 | 65846 | 110453604 |
| Suicide attempt | 11.98 | 9.78 | 30 | 69819 | 103364 | 110416086 |
| Toxic epidermal necrolysis | 11.84 | 9.78 | 11 | 69838 | 56716 | 110462734 |
| Ageusia | 11.69 | 9.78 | 33 | 69816 | 19612 | 110499838 |
| Retinitis | 11.67 | 9.78 | 3 | 69846 | 32324 | 110487126 |
| Application site erythema | 11.67 | 9.78 | 16 | 69833 | 5594 | 110513856 |
| Ventricular hypertrophy | 11.61 | 9.78 | 18 | 69831 | 7027 | 110512423 |
| Onychomycosis | 11.43 | 9.78 | 5 | 69844 | 38526 | 110480924 |
| Sciatica | 11.35 | 9.78 | 26 | 69823 | 92373 | 110427077 |
| Balance disorder | 11.30 | 9.78 | 118 | 69731 | 116442 | 110403008 |
| Heavy menstrual bleeding | 11.26 | 9.78 | 29 | 69820 | 16336 | 110503114 |
| Gallbladder disorder | 11.24 | 9.78 | 34 | 69815 | 20995 | 110498455 |
| X-ray abnormal | 11.22 | 9.78 | 5 | 69844 | 38112 | 110481338 |
| Syncope | 11.20 | 9.78 | 185 | 69664 | 202351 | 110317099 |
| Infective pulmonary exacerbation of cystic fibrosis | 11.02 | 9.78 | 27 | 69822 | 14744 | 110504706 |
| Wound drainage | 11.01 | 9.78 | 8 | 69841 | 1296 | 110518154 |
| Drug-induced liver injury | 10.91 | 9.78 | 39 | 69810 | 120028 | 110399422 |
| Delirium | 10.90 | 9.78 | 46 | 69803 | 134979 | 110384471 |
| Sedation | 10.85 | 9.78 | 17 | 69832 | 69666 | 110449784 |
| Injection site nodule | 10.81 | 9.78 | 14 | 69835 | 4632 | 110514818 |
| Very low density lipoprotein increased | 10.79 | 9.78 | 5 | 69844 | 347 | 110519103 |
| Lactic acidosis | 10.70 | 9.78 | 27 | 69822 | 92784 | 110426666 |
| Drug withdrawal syndrome | 10.67 | 9.78 | 50 | 69799 | 38004 | 110481446 |
| Multiple sclerosis | 10.56 | 9.78 | 38 | 69811 | 25660 | 110493790 |
| Application site pain | 10.42 | 9.78 | 15 | 69834 | 5484 | 110513966 |
| Tricuspid valve incompetence | 10.41 | 9.78 | 36 | 69813 | 23837 | 110495613 |
| Renal impairment | 10.35 | 9.78 | 73 | 69776 | 188372 | 110331078 |
| Left atrial dilatation | 10.35 | 9.78 | 12 | 69837 | 3548 | 110515902 |
| Abdominal pain | 10.34 | 9.78 | 409 | 69440 | 512580 | 110006870 |
| Diabetic retinopathy | 10.33 | 9.78 | 12 | 69837 | 3552 | 110515898 |
| Granulocytopenia | 10.31 | 9.78 | 24 | 69825 | 12691 | 110506759 |
| Musculoskeletal stiffness | 10.30 | 9.78 | 120 | 69729 | 279702 | 110239748 |
| Meniscus injury | 10.26 | 9.78 | 18 | 69831 | 7775 | 110511675 |
| Cardiac pacemaker insertion | 10.24 | 9.78 | 16 | 69833 | 6285 | 110513165 |
| Metabolic encephalopathy | 10.23 | 9.78 | 22 | 69827 | 11038 | 110508412 |
| Application site discolouration | 10.17 | 9.78 | 7 | 69842 | 1042 | 110518408 |
| Cyst | 10.10 | 9.78 | 28 | 69821 | 16468 | 110502982 |
| High density lipoprotein decreased | 9.94 | 9.78 | 15 | 69834 | 5718 | 110513732 |
| Pulse absent | 9.92 | 9.78 | 22 | 69827 | 11270 | 110508180 |
| Rash maculo-papular | 9.85 | 9.78 | 20 | 69829 | 74202 | 110445248 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C04AC01 | CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS PERIPHERAL VASODILATORS Nicotinic acid and derivatives |
| ATC | C10AD02 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Nicotinic acid and derivatives |
| ATC | C10AD52 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Nicotinic acid and derivatives |
| ATC | C10BA01 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
| FDA CS | M0014839 | Nicotinic Acids |
| MeSH PA | D000960 | Hypolipidemic Agents |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D014803 | Vitamin B Complex |
| MeSH PA | D014815 | Vitamins |
| MeSH PA | D018977 | Micronutrients |
| MeSH PA | D057847 | Lipid Regulating Agents |
| FDA EPC | N0000175594 | Nicotinic Acid |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:25212 | metabolite |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35679 | antilipemic drug |
| CHEBI has role | CHEBI:35821 | anticholesteremic drug |
| CHEBI has role | CHEBI:50247 | antidote |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:76924 | plant metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:84087 | human urinary metabolite |
| CHEBI has role | CHEBI:84264 | EC 3.5.1.19 (nicotinamidase) inhibitor |
| CHEBI has role | CHEBI:145947 | antiatherosclerotic agent |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
C04AC Nicotinic acid and derivatives 3 drugs
C10AD Nicotinic acid and derivatives 5 drugs
C10BA Combinations of various lipid modifying agents 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypercholesterolemia | indication | 13644009 | |
| Hyperlipidemia | indication | 55822004 | DOID:1168 |
| Vitamin deficiency | indication | 85670002 | |
| Familial hypercholesterolemia - heterozygous | indication | 238079002 | |
| Mixed hyperlipidemia | indication | 267434003 | |
| Hypertriglyceridemia | indication | 302870006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.31 | acidic |
| pKa2 | 4.85 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Hydroxycarboxylic acid receptor 2 | GPCR | AGONIST | Ki | 7.30 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Nicotinamide N-methyltransferase | Enzyme | WOMBAT-PK | |||||||
| Nicotinate-nucleotide pyrophosphorylase [carboxylating] | Enzyme | WOMBAT-PK | |||||||
| Nicotinamide phosphoribosyltransferase | Enzyme | WOMBAT-PK | |||||||
| Hydroxycarboxylic acid receptor 3 | GPCR | AGONIST | EC50 | 6.52 | IUPHAR | ||||
| Amyloid beta A4 protein | Membrane other | IC50 | 4.88 | CHEMBL | |||||
| Hydroxycarboxylic acid receptor 2 | GPCR | IC50 | 6.85 | CHEMBL | |||||
| Hydroxycarboxylic acid receptor 2 | GPCR | Ki | 7.48 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019440 | VUID |
| N0000147570 | NUI |
| D00049 | KEGG_DRUG |
| 4017632 | VANDF |
| 4017661 | VANDF |
| 4017718 | VANDF |
| 4019440 | VANDF |
| 4020285 | VANDF |
| 4021898 | VANDF |
| C0027996 | UMLSCUI |
| CHEBI:15940 | CHEBI |
| NIO | PDB_CHEM_ID |
| CHEMBL573 | ChEMBL_ID |
| 938 | PUBCHEM_CID |
| DB00627 | DRUGBANK_ID |
| 1588 | IUPHAR_LIGAND_ID |
| 218728 | RXNORM |
| 2275 | MMSL |
| 43641 | MMSL |
| 4947 | MMSL |
| 5169 | MMSL |
| 5170 | MMSL |
| 5684 | MMSL |
| 59920 | MMSL |
| 7159 | MMSL |
| 7161 | MMSL |
| 72420 | MMSL |
| d00314 | MMSL |
| d03739 | MMSL |
| 001052 | NDDF |
| 001055 | NDDF |
| 173196005 | SNOMEDCT_US |
| 273943001 | SNOMEDCT_US |
| 63639004 | SNOMEDCT_US |
| D009525 | MESH_DESCRIPTOR_UI |
| 373 | INN_ID |
| 2679MF687A | UNII |
| 2679MF687A | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3901 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 28 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3902 | TABLET, FILM COATED, EXTENDED RELEASE | 750 mg | ORAL | ANDA | 28 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3903 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 28 sections |
| VitafolOne | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0642-0070 | CAPSULE, GELATIN COATED | 15 mg | ORAL | unapproved drug other | 14 sections |
| Select OB | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0642-0077 | TABLET, CHEWABLE | 15 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
| Vitafol OBCaplet | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0642-0079 | TABLET | 18 mg | ORAL | unapproved drug other | 14 sections |
| Vitafol Plus | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0642-0092 | CAPSULE, LIQUID FILLED | 15 mg | ORAL | UNAPPROVED DRUG OTHER | 13 sections |
| Reaphirm Plant Source DHA | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0642-3010 | CAPSULE, GELATIN COATED | 15 mg | ORAL | unapproved drug other | 7 sections |
| O-Cal Prenatal Vitamin | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0813-0202 | TABLET | 17 mg | ORAL | UNAPPROVED DRUG OTHER | 6 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-612 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 25 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-613 | TABLET, EXTENDED RELEASE | 750 mg | ORAL | ANDA | 25 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-614 | TABLET, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 25 sections |
| JBA Collagen-Electrolyte Mocktail | HUMAN OTC DRUG LABEL | 12 | 13411-848 | POWDER | 18 mg | ORAL | unapproved drug other | 6 sections |
| TriStart DHA | HUMAN PRESCRIPTION DRUG LABEL | 15 | 15370-250 | CAPSULE, LIQUID FILLED | 5 mg | ORAL | UNAPPROVED DRUG OTHER | 12 sections |
| Niaspan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-852 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 26 sections |
| Niaspan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-865 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 26 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33342-187 | TABLET | 500 mg | ORAL | ANDA | 25 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33342-189 | TABLET | 1000 mg | ORAL | ANDA | 25 sections |
| NIACIN | Human Prescription Drug Label | 1 | 47335-539 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 27 sections |
| NIACIN | Human Prescription Drug Label | 1 | 47335-613 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 27 sections |
| NIACIN | Human Prescription Drug Label | 1 | 47335-614 | TABLET, FILM COATED, EXTENDED RELEASE | 750 mg | ORAL | ANDA | 27 sections |
| Multivitamin with fluoride | HUMAN PRESCRIPTION DRUG LABEL | 11 | 50090-0356 | TABLET, CHEWABLE | 13.50 mg | ORAL | UNAPPROVED DRUG OTHER | 8 sections |
| Multivitamin with fluoride | HUMAN PRESCRIPTION DRUG LABEL | 11 | 50090-0435 | TABLET, CHEWABLE | 13.50 mg | ORAL | UNAPPROVED DRUG OTHER | 8 sections |
| Multivitamin with Fluoride | HUMAN PRESCRIPTION DRUG LABEL | 12 | 50090-4475 | TABLET, CHEWABLE | 13.50 mg | ORAL | unapproved drug other | 10 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-584 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 19 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-584 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 19 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-586 | TABLET, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 19 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-586 | TABLET, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 19 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-267 | TABLET, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 25 sections |
| Niacin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-268 | TABLET, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 25 sections |